Instrument for Pre-accession Assistance (IPA) advanced EMA training on Quality and Inspections, European Medicines Agency, Amsterdam, the Netherlands, from 15 June 2023 to 16 June 2023

Submitted by Anonymous (not verified) on 15 January 2025 - 12:50

Instrument for Pre-accession Assistance (IPA) advanced EMA training on Quality and Inspections, European Medicines Agency, Amsterdam, the Netherlands, from 15 June 2023 to 16 June 2023

HMA/EMA multi-stakeholder workshop on artificial intelligence (AI) - enabling the safe and responsible use of AI, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 5 November 2024, 09:00 (CET) to 5 November 2024, 17:40 (CET)

Submitted by Anonymous (not verified) on 15 January 2025 - 12:31

HMA/EMA multi-stakeholder workshop on artificial intelligence (AI) - enabling the safe and responsible use of AI, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 5 November 2024, 09:00 (CET) to 5 November 2024, 17:40 (CET)

Table of decisions of labelling exemption requests falling under article 63 of Directive 2001/83/EC examined by the Quality Review of Documents (QRD) Group

Submitted by Anonymous (not verified) on 15 January 2025 - 12:22

Table of decisions of labelling exemption requests falling under article 63 of Directive 2001/83/EC examined by the Quality Review of Documents (QRD) Group

Timetable: Initial (full) marketing authorisation application accelerated assessment timetables - Advanced therapy medicinal product (ATMP)

Submitted by Anonymous (not verified) on 14 January 2025 - 16:31

Timetable: Initial (full) marketing authorisation application accelerated assessment timetables - Advanced therapy medicinal product (ATMP)

Human medicines European public assessment report (EPAR): Pheburane, sodium phenylbutyrate, Date of authorisation: 30/07/2013, Revision: 13, Status: Authorised

Submitted by Anonymous (not verified) on 14 January 2025 - 14:38

Human medicines European public assessment report (EPAR): Pheburane, sodium phenylbutyrate, Date of authorisation: 30/07/2013, Revision: 13, Status: Authorised

Policy 44: European Medicines Agency policy on the handling of competing interests of scientific committees’ members and experts - As adopted by EMA Management Board on 11-12 December 2024

Submitted by Anonymous (not verified) on 14 January 2025 - 14:07

Policy 44: European Medicines Agency policy on the handling of competing interests of scientific committees’ members and experts - As adopted by EMA Management Board on 11-12 December 2024

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness